



SMALL CELL LUNG CANCER (SCLC)

GLOBAL CLINICAL TRIAL LANDSCAPE (2024)



#DYK
Did you know?

SCLC is a fast growing and aggressive subtype, making up **10-15%** of global lung cancer cases




Marketed drugs for SCLC focus on **PD-1/PD-L1 inhibitors** (e.g., pembrolizumab, nivolumab) **and small molecules** like topotecan and lurbinectedin



Phase III trials are **advancing immunotherapies** (e.g., nivolumab) **and antibody-drug conjugates** (e.g., ifinatamab deruxtecan), showing promising progress in SCLC research

SMALL CELL LUNG CANCER TRIAL CONTRIBUTIONS

The Asia-Pacific region shows **recruitment rates** comparable to those of the United States



The content of this publication is proprietary to Novotech Health Holdings. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses. Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech. Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights. For permissions or inquiries, please contact: communications@novotech-cro.com